EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies

Xin Chen, Thomas Dong, Yuhui Hu, Raffaella De Pace, Rafael Mattera, Kathrin Eberhardt, Marvin Ziegler, Terry Pirovolakis, Mustafa Sahin, Juan S Bonifacino, Darius Ebrahimi-Fakhari, Steven J Gray

Journal of Clinical Investigation · 2023

DOI: 10.1172/jci164575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Xin Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Spastic Paraplegia, Hereditary. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Intramural NIH HHS, CureSPG50 Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spastic paraplegia 50 (SPG50) is an ultrarare childhood-onset neurological disorder caused by biallelic loss-of-function variants in the AP4M1 gene. SPG50 is characterized by progressive spastic paraplegia, global developmental delay, and subsequent intellectual disability, secondary microcephaly, and epilepsy. We preformed preclinical studies evaluating an adeno-associated virus (AAV)/AP4M1 gene therapy for SPG50 and describe in vitro studies that demonstrate transduction of patient-derived fibroblasts with AAV2/AP4M1, resulting in phenotypic rescue. To evaluate efficacy in vivo, Ap4m1-KO mice were intrathecally (i.t.) injected with 5 × 1011, 2.5 × 1011, or 1.25 × 1011 vector genome (vg) doses of AAV9/AP4M1 at P7-P10 or P90. Age- and dose-dependent effects were observed, with early intervention and higher doses achieving the best therapeutic benefits. In parallel, three toxicology studies in WT mice, rats, and nonhuman primates (NHPs) demonstrated that AAV9/AP4M1 had an acceptable safety profile up to a target human dose of 1 × 1015 vg. Of note, similar degrees of minimal-to-mild dorsal root ganglia (DRG) toxicity were observed in both rats and NHPs, supporting the use of rats to monitor DRG toxicity in future i.t. AAV studies. These preclinical results identify an acceptably safe and efficacious dose of i.t.-administered AAV9/AP4M1, supporting an investigational gene transfer clinical trial to treat SPG50.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spastic Paraplegia, HereditaryHumansRatsMiceAnimalsChildGenetic TherapyDependovirusGenetic VectorsParaplegia

Stichwörter der Autor:innen

Neurological disordersNeuroscience

Autor:innen und Institutionen

  • Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Neurosciences and Cellular and Structural Biology Division, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.
  • Department of Neurology and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • CureSPG50 Foundation, Toronto, Ontario, Canada.

Förderung

  • NICHD NIH HHS
  • Intramural NIH HHS
  • CureSPG50 Foundation

Zitieren

APA

Chen, X., Dong, T., Hu, Y., De Pace, R., Mattera, R., Eberhardt, K., Ziegler, M., Pirovolakis, T., Sahin, M., Bonifacino, J. S., Ebrahimi-Fakhari, D., & Gray, S. J. (2023). Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies. Journal of Clinical Investigation. https://doi.org/10.1172/jci164575

Vancouver

Chen X, Dong T, Hu Y, De Pace R, Mattera R, Eberhardt K, et al. Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies. Journal of Clinical Investigation. 2023. doi:10.1172/jci164575

BibTeX
@article{Chen2023,
  author = {Chen, Xin and Dong, Thomas and Hu, Yuhui and De Pace, Raffaella and Mattera, Rafael and Eberhardt, Kathrin and Ziegler, Marvin and Pirovolakis, Terry and Sahin, Mustafa and Bonifacino, Juan S and Ebrahimi-Fakhari, Darius and Gray, Steven J},
  title = {Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci164575}
}
Kostenlos starten →